Molecular

Oncology experts with the University of Washington in Seattle’s Cancer Research Center shared their findings in the Journal of Nuclear Medicine's February issue.

SNMMI said it is working with the Centers for Medicare & Medicaid Services and the manufacturer of Cerianna to remedy the problem.

By actively tracking amyloid-beta and tau, Massachusetts General Hospital researchers may be able to diagnose the deadly disease earlier. 

In light of their findings, University of Copenhagen experts also believe 64Cu-labeled PET tracers will become more commonplace for clinical use.

That’s according to a study of more than 400 dementia-free British citizens, shared recently in Brain.

As part of the contract, Los Angeles-based ImaginAb will provide Pfizer will its 89Zr CD8 immuno-PET agent, which is used to image CD8 T cells in cancer patients.

This marks the first and only commercial-scale application of concentrated molybdenum-98 technology, the Beloit, Wisconsin-based firm said recently.

“This offers the potential to provide diagnostic imaging using copper-64 to plan individualized treatments with copper-67 agents for a wide range of cancer patients," Australian researchers explained in the Journal of Nuclear Medicine.

By 2022, the company said its facility will be fully operational and capable of producing more than 300,000 doses of lutetium-177 each year.

The manganese-based contrast was also expelled more rapidly and completely from the body compared to other imaging agents.

MRI is the current standard imaging modality used for this disease, but it falls short in many key areas, German researchers explained recently.

Beginning in the 1960s, the new edition traces such milestones as the invention of the Anger camera and the development of positron emission tomography.